ghk-cu mechanism of action receptor desensitization Structural insights into kainate GHK Peptide as a Natural – Copper Peptide and PDRN. A

After 46 weeks of treatment: 0.6 mg dose: 6.2% mean body weight reduction 2.4 mg dose: 12.5% mean body weight reduction 3.6 mg dose: 13.2% mean body weight reduction 4.8 mg dose: 14.9% mean body weight reduction (all randomized) 4.8 mg dose: 18.7% mean body weight reduction (completers only) Placebo: 2.8% mean body weight reduction Among completers at the 4.8 mg dose, 68.8% achieved at least 10% weight loss, 67% achieved at least 15%, and 40% achieved at least 20% weight loss

This peptide is a growth hormone-releasing hormone (GHRH) fragment that includes the first 29 amino acids of its N-terminus and an amidation at its C-terminus

Pen Dosage Chart Dosage & Protocols Variations Standard Research Protocol Dose: 1.0 5.0 mg (= 20100 clicks) Duration: 3 consecutive days Frequency: Once every 2 weeks (intermittent pulse) Cycle Interval: 2 4 weeks off before repeating Goal / Description: Baseline senolytic pulsing observed in preclinical aging models

NAD+ is also available as part of an IM Shot